Author Archives: Danzig

Astronauts back on Earth after ‘extraordinary’ Dragon test flight – Spaceflight Now

Posted on by

SpaceXs Crew Dragon spacecraft splashes down in the Gulf of Mexico Sunday with two NASA astronauts on-board. Credit: NASA/Bill Ingalls

Returning home after a 64-day test flight, astronauts Doug Hurley and Bob Behnken blazed through Earths atmosphere and parachuted into the Gulf of Mexico inside a SpaceX Crew Dragon spacecraft Sunday, a final major step before NASA formally certifies the crew capsule for operational missions to the International Space Station.

The successful homecoming for Hurley and Behnken signaled a turning point in NASAs commercial crew program, which fostered public-private partnerships with U.S. companies to design, develop and fly new human-rated space taxis after the retirement of the space shuttle.

The astronauts launched inside SpaceXs Crew Dragon spaceship May 30, when they rode a Falcon 9 rocket into orbit from the Kennedy Space Center. The launch was the first time a crew rocketed into orbit from U.S. soil since the last space shuttle flight in 2011.

With Sundays splashdown in the Gulf of Mexico, NASA is on the verge of certifying the Crew Dragon spacecraft for regular trips to and from the space station. That will allow the space agency to end its reliance on Russia for crew transportation.

This has been quite an odyssey the last, five, seven, eight years five years since Bob and I started working on this program, Hurley said after Sundays return. And to be where we are now, (with) the first crewed flight of Dragon, is just unbelievable.

Not only was Sundays splashdown a major milestone for NASA, it also made history in the realm of commercial spaceflight. The Crew Dragon became the first privately-owned spacecraft to carry a crew into orbit and return them safely to Earth.

I do think what this heralds really is fundamentally a new era in spaceflight, a new era in space exploration, said Elon Musk, SpaceXs founder and CEO, in remarks Sunday evening in Houston to welcome home Hurley and Behnken. Were going to go to the moon. Were going to have a base on the moon. Were going to send people to Mars, and make life multi-planetary.

After detaching from the International Space Station on Saturday night, the Dragon spacecraft carrying Hurley and Behnken lined up for a southwest-to-northeast approach to a splashdown zone in the Gulf around 34 miles (54 kilometers) off the Florida coast near Pensacola.

The capsule jettisoned its unpressurized trunk section with the ships solar panels and thermal control radiator just before firing a set of Draco rocket jets at 1:56 p.m. EDT (1756 GMT) for a deorbit burn lasting more than 11 minutes.

The braking burn changed the capsules velocity enough toallow Earths gravity to pull the spacecraft back into the atmosphere, which did the rest of the work to slow Dragons speed from 17,500 mph (28,000 kilometers per hour) to just 15 mph (24 kilometers per hour) for splashdown.

The spacecraft closed its nose cone a few minutes later, then encountered the uppermost fringes of the discernible atmosphere at 2:36 p.m. EDT (1836 GMT).

Wearing their white SpaceX-madeflame-resistant pressure suits, the astronauts experienced up to 4Gs during entry. The capsule flew on autopilot, pointing its blunt end into the airflow as temperatures outside the spacecraft rose up to 3,500 degrees Fahrenheit (over 1,900 degrees Celsius).

A plasma sheath enshrouded the capsule for several minutes, causing an expected communication blackout between the Crew Dragon which Hurley and Behnken named Endeavour and SpaceX mission control in Hawthorne, California.

Ground teams restored the voice link with the Dragon astronauts, and a pair of drogue parachutes unfurled to stabilize the capsule. Four orange and white main parachutes deployed at an altitude of about 18,000 feet (5,500 meters) to slow the capsules descent in the last few minutes before splashdown.

The 13-foot-wide (4-meter), 16-foot-tall (5-meter) capsule splashed down at 2:48 p.m. EDT (1848 GMT).

Endeavour, on behalf of the SpaceX and NASA teams, welcome back to planet Earth, radioed SpaceXs spacecraft communicatorMike Heiman. Thanks for flying SpaceX.

It was truly our honor and privilege to fly the (first) flight of the Crew Dragon Endeavour, Hurley replied moments after splashdown. Congratulations to everybody at SpaceX.

The splashdown near Pensacola was the first time U.S. astronauts returned from a space mission with a splashdown at sea since 1975, when the Apollo-Soyuz Test Project mission came back to Earth. It was also the first splashdown of astronauts in the Gulf of Mexico.

Hurley and Behnkens mission known as Demo-2, or DM-2 lasted 64 days since they blasted off from Floridas Space Coast on May 30.

After reaching the space station May 31, the astronauts joined the Expedition 63 led by commander Chris Cassidy.

Cassidy and his two Russian crewmates Anatoly Ivanishin and Ivan Vagner will remain aboard the space station until October, when they will return to a landing in Kazakhstan on a Russian Soyuz spacecraft. Three fresh crew members will launch to the space station Oct. 14 on a new Soyuz spaceship.

During their two-month stay, Hurley and Behnken assisted Cassidy, Ivanishin and Vagner with space station duties, performing experiments and maintenance. Behnken joined Cassidy on four spacewalks in June and July to replace batteries on the space stations solar power modules.

A SpaceX recovery vessel named Go Navigator was on station in the Gulf of Mexico to retrieve the Crew Dragon spaceship after it splashed down.

Two fast boats with recovery team members approached the capsule. After ensuring the spacecraft was safe, the larger recovery boat took position near the Dragon and hoisted the capsule out of the water using a lifting frame.

Once the Dragon was on the deck of Go Navigator, SpaceX technicians detected elevated levels of nitrogen tetroxide outside the spacecraft. The compound is used as an oxidizer for the spacecrafts maneuvering thrusters, and is highly toxic.

The recovery team purged part of the spacecraft to rid it of the toxic contaminants before opening the hath and helping Hurley and Behnken out of the capsule for initialmedical checks.

SpaceX said the recovery ship had around 44 people on-board, including SpaceX and NASA officials, doctors, nurses and other medical personnel. Spacecraft technicians were aboard to recover and secure the Dragon capsule.

Hurley and Behnken later rode a helicopter to Naval Air Station Pensacola, where they boarded a NASA aircraft for the flight back to their home base in Houston.

The astronauts came back to Earth with around 330 pounds (150 kilograms) of cargo, including frozen experiment specimens, personal gear, and a U.S. flag left on the space station by the final space shuttle crew in 2011.

Hurley was the pilot on the final space shuttle flight.

The flag also flew on STS-1, the first shuttle mission, in 1981. The final shuttle crew left it on the space station to be returned by the next astronauts to fly to the research lab on a U.S. spacecraft.

In the end, SpaceX won the capture the flag competition on the high frontier.

NASA awarded multibillion-dollar contracts to develop and fly new U.S.-built commercial crew capsules to SpaceX and Boeing in 2014, following several years of preliminary design work.

SpaceX, founded by Musk 18 years ago, launched a successful unpiloted Crew Dragon demonstration flight to the space station in March 2019, then overcame a setback during ground testing of the Crew Dragons launch abort system last year. After redesigning part of the abort system, and verifying new modifications to the capsules parachutes, SpaceX launched the first Crew Dragon mission with astronauts May 30.

Boeings CST-100 Starliner crew capsule launched into orbit for its first unpiloted test flight last December, but it ran into software problems that prevented the spacecraft from reaching the space station. Boeing recovered the spacecraft with a successful landing in New Mexico, but officials plan to re-fly the uncrewed demonstration mission later this year before clearing the Starliner to carry astronauts for the first time in 2021.

SpaceX has signed contracts with NASA on the Crew Dragon program valued at more than $3 billion. Boeing has a similar set of agreements with NASA worth more than $5 billion for the Starliner program.

Both companies have contributed undisclosed sums to the Crew Dragon and Starliner programs from their own corporate funds.

NASA says contracting out human spaceflight missions to low Earth orbit will reduce costs, freeing limited government funding for astronaut journeys to the moon, and eventually Mars.

With the Crew Dragons first round-trip space mission with astronauts in the books, SpaceX and NASA will analyze data from the Demo-2 test flight before formally certifying the commercial capsule for operational crew rotation launches.

The first such regular crew rotation flight, named Crew-1, is scheduled for launch this fall on a SpaceX Falcon 9 rocket from the Kennedy Space Center. Four astronauts are assigned to the Crew-1 flight.

Well do a few things to get ready for certification in a few different areas, said Steve Stich, manager of NASAs commercial crew program. One, well review all the telemetry, all the data from the Dragon. Weve done that for the whole flight to date. Well do that now for undocking all the way through splashdown and recovery.

We do it jointly with SpaceX, said Stich, a former NASA flight director. We have our NASA team and SpaceX working together and going through all the data for each of the various systems life support, propulsion, and so forth. So well go through all that data to make sure that theres nothing anomalous there.

Second, well look at the parachutes, Stich said. The parachutes are a very important system on the vehicle. SpaceX was doing a great job of recovering their chutes today, so well take those back and analyze those, look at it, just to see if they performed well.

The Dragon capsule that flew Hurley and Behnken into space will fly again on the Crew-2 mission next year. Gwynne Shotwell, SpaceXs president and chief operating officer, said Sunday the companys new Dragon spacecraft design which comes in crew and cargo variants should be capable of five to 10 flights.

One of the benefits of reuse, I would say, is the fact that well take some of the vehicle apart, Stich said. The nose cone will come off, the heat shield comes off, well start to inspect part of the spacecraft, and sometimes we can learn things from that.

So well do that inspection, and then well put all that together and head into the certification review, probably toward the end of this month or early next month.

Subsequent Crew Dragon missions to the space station will also launch with up to four passengers, and the spaceship once certified after Demo-2s return will be capable of missions lasting up to 210 days.

While SpaceXs core market for crew missions is with NASA and government astronauts, the company has its eyes set on flying commercial passengers. Earlier this year, SpaceX announced agreements with Axiom Space and Space Adventures, two companies that are arranging orbital expeditions with space tourists, paying passengers, and other would-be space fliers in the private sector.

One future Crew Dragon passenger could be Tom Cruise, who is planning to film a movie in orbit through a partnership with SpaceX, according to the entertainment website Deadline.

This was an extraordinary mission, an extraordinary day for NASA, for SpaceX, and frankly for Americans and anyone interested in spaceflight, Shotwell said Sunday, referring to the conclusion of the Demo-2 test flight. This is really just the beginning. We are starting the journey of bringing people regularly to and from low Earth orbit, and on to the moon, and ultimately on to Mars.

Email the author.

Follow Stephen Clark on Twitter: @StephenClark1.

Read the original post:

Astronauts back on Earth after 'extraordinary' Dragon test flight - Spaceflight Now

The Vostok Program: The Soviet’s first crewed spaceflight program – Space.com

Posted on by

The Vostok program was a Soviet space program project that ran from 1960 to 1963 and achieved many spectacular milestones in spaceflight, including placing the first man in space, the first woman in space, and the first joint flight of two different crewed orbiters.

Vostok took place at the beginning of the space race, a series of competitive technology demonstrations between the United States and the Soviet Union, aiming to show superiority in spaceflight during the Cold War. The USSR was largely seen to be ahead in the early days of the space race.

Russia has a long and prestigious history of thinking about human spaceflight, all the way back to the pioneering work of engineer and mathematician Konstantin Tsiolkovsky, who in 1903 first derived the rocket equation, which describes the movement of spacefaring vehicles. This helped give the Soviet Union a leg up at the dawn of the Space Age.

After launching Sputnik, the first artificial satellite, in 1957, the USSR began preparations for crewed missions, which included developing the Vostok spacecraft that would carry people into space, according to Astronautix.com, a website about space history. These spacecraft were placed atop the Vostok rocket, a 98-foot (30-meter) launch vehicle slightly larger than those used in NASA's Mercury program.

Between 1960 and '61, the Soviets launched several test Vostok capsules containing dogs, some of which were killed during their missions and some of which survived and landed safely on Earth, according to Russianspaceweb.com.

Related: Laika the dog & the first animals in space

History was made on April 12, 1961 when Yuri Gagarin became the first human to fly in space and orbit the Earth during the Vostok 1 mission. Gagarin's flight lasted a short 108 minutes, as he travelled once around our planet before reentering the atmosphere.

Because engineers were uncertain about how weightlessness would affect Gagarin, the spherical one-person Vostok capsule had little in the way of onboard controls, with most actions being coordinated by planners on the ground. In case of an emergency, Gagarin was given an override code allowing him to take manual control.

The cramped Vostok cabin was only about 8 feet (2.5 m) in diameter and made of aluminum alloy. It sported two windows: One above the cosmonaut's head in the entry hatch and one at his feet. During that first flight, the capsule contained 10 days' worth of provisions in case the engines failed and Gagarin was required to wait for the orbit to naturally decay.

The Vostok spacecraft had no real maneuvering capabilities and couldn't land on its own. After reentry, Gagarin ejected from the spacecraft about 4 miles (7 kilometers) up and parachuted to the ground, landing in a potato field and startling a farmer and her granddaughter, according to Russianspaceweb.com.

Gagarin became a national and international hero, with hundreds of thousands of people cheering him during a celebratory parade in Red Square, a public plaza in Moscow. The anniversary of his flight is commemorated as "Cosmonautics day" in Russia.

On Aug. 6, 1961, the USSR launched Vostok 2, which carried cosmonaut Gherman Titov, who became the fourth person in space after American astronauts Alan Shepard and Virgil Grissom flew suborbital flights for NASA's Mercury program. Titov became the first person to stay in space for more than a day, orbiting the Earth 17.5 times over the course of 25 hours, according to the New Zealand website Daryl's Space Collection.

Titov had been Gagarin's backup pilot for Vostok 1, and Vostok 2 was his only spaceflight. After his flight, he was grounded for medical reasons as he had the unfortunate honor of being the first person to experience space sickness, having been so nauseated that he could barely eat during his mission, according to Russianspaceweb.com.

Vostok 3 and 4 was a daring double mission in which two separate spacecraft launched within a day of each other, on Aug. 11 and 12, 1962. Cosmonaut Andriyan Nikolayev rode on Vostok 3 and Pavel Popovichflew aboard Vostok 4.

The simultaneous spacecraft were a response to the U.S. managing to successfully orbit one of their astronauts, John Glenn, earlier that year. The Soviets decided to show their superiority by demonstrating "formation flights" in space, according to Russianspaceweb.com.

Vostok 3 launched first and was in position when Vostok 4 arrived in orbit, with the two spacecraft coming within 3 miles (5 kilometers) of one another after Vostok 4's launch. The two pilots made radio contact with one another and Popovich reported being able to see Nikolayev's ship. But without maneuvering capabilities, the two soon drifted apart, according to Astronautix.com.

Vostok 4 had problems with its life support system, and the capsule's internal temperature dropped to 50 degrees Fahrenheit (10 degrees Celsius). The pilot, Popovich, still wanted to complete his mission but had been told to radio ground control and say he was "observing thunderstorms" in case he felt space-sick like Titov.

Popovich, in fact, saw thunderstorms over the Gulf of Mexico and told mission control about it, which they then mistakenly took for the secret signal. He was brought down early, landing within a few minutes of Vostok 3. Each had been up for a few days.

The final two Vostok flights were another double mission. Vostok 5 launched June 14, 1963 and Vostok 6 on June 16, 1963, and the two spacecraft once again passed within 3 miles (5 km) of one another and established radio contact, according to Astronautix.com.

Vostok 5 carried cosmonaut Valery Bykovsky, whose five-day flight remains the longest solo spaceflight in Earth orbit to this day, according to Daryl's Space Collection.

Vostok 6 set an even more impressive record, carrying the first woman into space, Valentina Tereshkova. The idea for a female cosmonaut came from Sergei Korolev, the chief architect of the Soviet space program.

But Korolev was unhappy with Tereshkova's performance and wouldn't allow her to take manual control of the craft, as had been planned. It took another 19 years before another woman, Svetlana Savitskaya, flew in space and more than two decades before NASA launched a female astronaut, Sally Ride.

Related: Women in space: A gallery of fights

Several other Vostok flights had been in the planning stages, including a double mission involving two women and much longer solo flights, according to Astronautix.com. But these were all superseded by the Soviet Voskhod program, which conducted multi-person crews, and the Soyuz program, which remains the name for Russia's crewed spaceflight missions.

Additional resources:

Here is the original post:

The Vostok Program: The Soviet's first crewed spaceflight program - Space.com

Sixers look to bounce back tonight against the Spurs – Liberty Ballers

Posted on by

Remember how excited we were for the return of Sixers basketball? Oh, how young and naive we were. While the worst case scenario of a major injury didnt transpire, its safe to say the heart of every optimistic Sixers fan was injured in Saturday nights excruciating loss to the Indiana Pacers. But you cant pronounce the word fanatic without the word addict, and were back for another hit of potential heartbreak tonight when Philadelphia takes on the San Antonio Spurs.

People had essentially written off the Spurs as an afterthought within the bubble. San Antonio is in the midst of a record-tying 22-year playoff streak, but the Spurs had the second-worst record among Western Conference teams invited to the bubble. With seven-time All-Star LaMarcus Aldridge sidelined after undergoing shoulder surgery in June, people basically assumed that streak was coming to an end. Even Gregg Popovich said two weeks ago that his main goal was elsewhere (courtesy of NBC Sports):

Each team has a goal here. Some teams are confident theyre a step away from winning an NBA championship. Other teams just want to be in the playoffs. Some teams are concerned mainly with development. If we play well enough to get into the playoffs, that would be great. But my goal is development right now.

However, the Spurs have opened the restart period with wins over Sacramento and Memphis. Suddenly, they find themselves in sole possession of ninth place in the West, just two games back of the Grizzlies. While veteran DeMar DeRozan remains a consistent contributor, San Antonio is succeeding in large part due to expanded roles for their young backcourt. Third-year guard Derrick White went off for 26 points, eight rebounds, and five assists against the Kings, and then fellow third-year guard Dejounte Murray led the team in scoring with 21 points and 10 rebounds against Memphis. Popovich has also inserted second-year player Lonnie Walker into the starting lineup, basically starting four guards in order to serve the youth movement.

One of the few positive takeaways for the Sixers on Saturday was the play of Joel Embiid, who exploded for 41 points and 21 rebounds. He should find similar success against San Antonio, who is depleted in the frontcourt with Aldridge out in addition to fellow starter Trey Lyles. Jakob Poeltl has been starting at center for the Spurs, and he can be very foul-prone; Poeltl fouled out in just 20 minutes yesterday against Memphis.

So thats one positive for the Sixers, as is the fact that theyre catching San Antonio on the tail end of a back-to-back a rarity in bubble play. You would also expect the various Sixers ball handlers to remember how to throw a simple pass, something that eluded them to a great extent two nights ago. Throw in the possibility of more than four combined points from Philadelphias starting backcourt and one fewer expletive-laden flare-up between starters on the sideline and you have to feel better about the Sixers chances this evening.

The real reason Sixers fans should feel confident about a victory tonight, though: its nominally a Sixers home game.

Injuries:Philadelphia: Mike Scott - out (knee); Zhaire Smith - out (knee); Glenn Robinson III - doubtful (hip pointer)San Antonio: LaMarcus Aldridge - out (shoulder surgery); Trey Lyles - out (appendicitis); Bryn Forbes - questionable (quad tightness); Marco Belinelli - questionable (ankle)

Who: Philadelphia 76ers vs. San Antonio SpursWhere: ESPN Wide World of Sports Complex, Orlando, FL (The Bubble)When: 8:00pm ETWatch: NBC Sports PhiladelphiaListen: 97.5 The Fanatic

View post:

Sixers look to bounce back tonight against the Spurs - Liberty Ballers

Have You Seen This? Dramatic lightning bolt lights up Statue of Liberty – KSL.com

Posted on by

THE END TIMES There are five months left in the year 2020 and, at this point, if fire and brimstone rain down from the heavens, I wont be surprised. Is it really a month of 2020 if existential crises dont pop up like a game of whack-a-mole on expert mode? I think not.

There's been the plagues, earthquakes and even a scare with giant locusts. The curse in the proverb may you live in interesting times has become woefully clear. This dramatic video of a lightning bolt menacing the Statue of Liberty feels symbolic of the whole year. Take a look.

As severe storms thundered through New York City last week, Americas patron green-stained statue of freedom and acceptance is a constant target. The lightning in this video only seems to strike Lady Liberty (it's in the distance behind her, according to ABC News), but apparently, the copper statue is hit by lightning an estimated 600 times a year, so this onslaught is nothing new. That doesn't make it feel less legendary.

The lightning in this video lingers and re-ignites like a deity angry at its people; and if you told me this video came from the opening montage of an apocalyptic movie, Id believe you and say the filmmakers were heavy-handed on their symbolism. Lay off, Jeff from the SFX department, the real world is not so poetic! I mightve rolled my eyes. Except, you know, Jeff was right and a 10th grader with a flair for edgy symbolic cheap shots is now apparently writing reality.

So sit back, grab your popcorn and watch this video on repeat like the overly-ominous and wickedly cool sign of the times it feels like.

Correction: This story initially said the video shows the Statue of Liberty being repeatedly struck by lightning; it has been corrected to say that the lightning strikes in the distance behind the statue.

Read more:

Have You Seen This? Dramatic lightning bolt lights up Statue of Liberty - KSL.com

Global Nanosensors Market Huge Growth CAGR of 90.1% by 2026 | With Top Players- Linear Technologies, NXP Semiconductor, InvenSense, Knowles, Analog…

Posted on by

Global Nanosensors Market By Product Type (Mechanical, Biological and Chemical Nanosensors), By Application (Security, Surveillance and Military, Biomedical and Healthcare, Environmental Monitoring, Food Management and others) By End Users (Aerospace, Environmental Monitoring, Healthcare and others), By Geography (North America, South America, Europe, Asia-Pacific, Middle East and Africa) Industry Trends and Forecast to 2025

Global Nanosensors Market research report gives the most appropriate and specific information to the decision-makers in the industry which saves their time and result in excellent output. The report carefully analyses the potential of the market with respect to the current scenario and future prospects with respect to several industry aspects. This Global Nanosensors Market report explains several market factors such as market estimates and forecasts, entry strategies, opportunity analysis, market positioning, competitive landscape, product positioning, market assessment, and viability studies. The best solution is offered with the systematic study of all these parameters that are performed by the experts.

Nanosensors Marketis expected to reach USD 15,434.96 Million by 2025, from USD 90.5 Million in 2017 growing ata CAGR of 90.1%during the forecast period of 2018 to 2025. The upcoming market report contains data for historic years 2014 & 2015, the base year of calculation is 2016 and the forecast period is 2018 to 2025.

Get Sample Report + All Related Graphs & Charts @http://databridgemarketresearch.com/request-a-sample/?dbmr=global-nanosensors-market

Major Market Competitors/Players:Global Nanosensors Market

Some of the major players operating in the market are Linear Technologies, NXP Semiconductor, InvenSense, Knowles, Analog Devices, Texas Instruments, STMicroelectronics, Hitachi, Nanomix, Murata Manufacturing, Atmel, Banner Engineering, ams, Rockwell Automation, TOWA, and Panasonic among others.

Competitive Analysis:

The Global Nano Sensors market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of absorbable and non-absorbable sutures market for global, Europe, North America, Asia Pacific and South America.

The current trend pertaining to the demand supply and sales together with the recent developments have been given here to provide an exhaustive picture of this market. It also allows voluntarily accessible affordable reports of the research that is the end result of the personalized research carried by the internal team of professionals.

To comprehend Global Nanosensors market dynamics in the world mainly, the worldwide Nanosensors market is analyzed across major global regions.

Actual Numbers & In-Depth Analysis, Business opportunities, Market Size Estimation Available in Full Report.

Market Definition:

Nano sensors consist of nanomaterials or nano-chemicals used in monitoring moisture, temperature, and pressure. Nano sensors based devices are used in diagnostic machines. The main reason behind the use of nano-sensors in diagnostic kits is that nano-sensors even detect the minute change in the blood, urine sample or other samples. Nano-sensor devices detects the conditions in very early stage based on Nano sensors have wide mechanical, chemical and biological applications. Nanosensors have wide application in gas sensing technologies like RFID (Radio-frequency identification) systems have gas sensing capabilities. Zinc Oxide based nanosensors are used in modified electrodes and enzyme immobilization and biosensors performance. In Blood coagulation carbon nanotubes are used for detecting proteins, fibrinogen and coagulation factors.

Major Market Drivers and Restraints:

Table of Contents-Snapshot Executive SummaryChapter 1 Industry OverviewChapter 2 Industry Competition by ManufacturersChapter 3 Industry Production Market Share by RegionsChapter 4 Industry Consumption by RegionsChapter 5 Industry Production, Revenue, Price Trend by TypeChapter 6 Industry Analysis by ApplicationsChapter 7 Company Profiles and Key Figures in Industry BusinessChapter 8 Industry Manufacturing Cost AnalysisChapter 9 Marketing Channel, Distributors and CustomersChapter 10 Market DynamicsChapter 11 Industry ForecastChapter 12 Research Findings and ConclusionChapter 13 Methodology and Data Source

Key Developments in the Market:

Grab Your Report at an Impressive 30% Discount! Please click Here @http://databridgemarketresearch.com/inquire-before-buying/?dbmr=global-nanosensors-market

About Data Bridge Market Research:

Data Bridge Market Researchset forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Contact:

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Email:[emailprotected]

See original here:

Global Nanosensors Market Huge Growth CAGR of 90.1% by 2026 | With Top Players- Linear Technologies, NXP Semiconductor, InvenSense, Knowles, Analog...

Shaft Measuring Machine Market Business Overview, Revenue, Price and Gross Margin, Product Specifications, Forecast 2025 – Owned

Posted on by

Analysis of the Global Shaft Measuring Machine Market

The presented global Shaft Measuring Machine market report provides reliable and credible insights related to the various segments and sub-segments of the market. The market study throws light on the various factors that are projected to impact the overall dynamics of the global Shaft Measuring Machine market over the forecast period (20XX-20XX).

According to the report, the value of the Shaft Measuring Machine market was estimated to reach ~US$ XX in 2019 and attain a market value of ~US$ XX by the end of 2029. Further, the study reveals that the market is set to grow at a CAGR of XX% during the forecast period owing to a plethora of factors.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.marketresearchhub.com/enquiry.php?type=S&repid=2742768&source=atm

The market study aims to provide answers to the following questions related to the Shaft Measuring Machine market:

The report splits the global Shaft Measuring Machine market into different market segments such as:

The region-wise segmentation offers critical information such as the market share, size, revenue analysis, growth prospects, and market attractiveness of each region.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.marketresearchhub.com/enquiry.php?type=E&repid=2742768&source=atm

Segment by Type, the Shaft Measuring Machine market is segmented intoMulti-SensorOpticalMechanical

Segment by Application, the Shaft Measuring Machine market is segmented intoAutomotiveElectric & ElectronicMechanicalOthers

Regional and Country-level AnalysisThe Shaft Measuring Machine market is analysed and market size information is provided by regions (countries).The key regions covered in the Shaft Measuring Machine market report are North America, Europe, China and Japan. It also covers key regions (countries), viz, the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc.The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of production capacity, price and revenue for the period 2015-2026.Competitive Landscape and Shaft Measuring Machine Market Share Analysis

Shaft Measuring Machine market competitive landscape provides details and data information by manufacturers. The report offers comprehensive analysis and accurate statistics on production capacity, price, revenue of Shaft Measuring Machine by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on production, revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue, and the production capacity, price, revenue generated in Shaft Measuring Machine business, the date to enter into the Shaft Measuring Machine market, Shaft Measuring Machine product introduction, recent developments, etc.The major vendors covered:WenzelChien Wei Precise TechnologyRenishaw PlcCreaformHelmel Engineering ProductsWerth Messtechnik GmbHXian High-TechAeh Industrial MetrologyGroup,Nano (Xian) MetrologyAberlink LtdZeiss International (Subsidiary Of Carl-Zeiss-Stiftung)Faro TechnologiesHexagon ABMitutoyo CorporationNikon Metrology NVPerceptronDUKINInternational Metrology SystemsMetronorTRIMEK

Vital data enclosed in the report:

You can Buy This Report from Here @ https://www.marketresearchhub.com/checkout?rep_id=2742768&licType=S&source=atm

Read more here:

Shaft Measuring Machine Market Business Overview, Revenue, Price and Gross Margin, Product Specifications, Forecast 2025 - Owned

Election 2020: Oregon psilocybin and drug decriminalization initiatives guide – Leafly

Posted on by

The latest news on IP 34 and IP 44, Oregons drug reform initiatives

July 29 Oregons state Criminal Justice Commission released an analysis of the impact of IP 44, the statewide initiative to decriminalize small amounts of all drugs, on different racial and ethnic groups. The results, according to The Oregonian:

The draft racial and ethnic impact statement prepared by the Criminal Justice Commission suggests there would be a significant decrease in misdemeanor and felony drug possession convictions across demographic groups, if voters decide to decriminalize possession of small amounts of all drugs. Total convictions for Asian Oregonians could fall by 82.9%, for Latinos by 86.5%, for whites by 91.1%, for Blacks by 93.7% and for Native Americans by 94.2%.

Read the full text of the proposal here:Oregon Psilocybin Program Initiative (Initiative 34) (therapeutic use of psilocybin)

Read the full text of the proposal here:Oregons Drug Addiction Treatment and Recovery Act (Initiative 44) (all-drug decriminalization and treatment)

Wellboth.

IP 34 (psilocybin) would legalize the medical use of psilocybin under the care of a licensed facilitator.

IP 44 (all-drug decrim) would decriminalize all drugs.

Its unclear whether IP 44, if passed, would make IP 34 redundant, as IP 44 would make possession of psilocybin no longer a criminal act.

Initiative 34, the Oregon Psilocybin Program Initiative, would create a program and screening process for providing psilocybin to individuals 21 years of age or older. Consumption would be supervised by licensed facilitators, and the program would exist under the purview of the Oregon Health Authority, as well as an advisory board of 14-16 individuals appointed by the governor. The measure requires a two-year development period for the Oregon Health Authority to lay out regulations for the program.

Initiative 44, Oregons Drug Addiction Treatment and Recovery Act is the first measure of its kind to reach a statewide ballot in the United States. It would remove criminal penalties for the personal, non-commercial possession of all drugs listed as Schedule I, II, III, or IV by the federal Controlled Substances Act. Possession of small quantities would be classified as a violation similar to a speeding ticket. Penalties would be a $100 fine and/or a health assessment at an addiction recovery center.

IP 44 would alsoprovide holistic, wide-reaching treatment to drug users, including housing and accessible consultations with social service providers. The proposed program would be funded almost exclusively through $100 million in annual cannabis tax revenue.

Initiative 44 (drug decrim): No. Initiative 44 removes drug possession as an arrestable offense. There are no provisions within the initiative to allow or regulate the sale of drugs. I-44 does not remove or invalidate the states current regulations regarding the manufacture and sale of alcohol and cannabis.

Initiative 34 (psilocybin):Yes. The Oregon Psilocybin Services Program would license and regulate producers, processors, delivery services and possession of psilocybin exclusively for the administration of psilocybin services by licensed facilitators to qualified clients.

Initiative 44 (drug decrim): No. Because Initiative 44 does not allow or regulate the legal sale of drugs aside from alcohol and cannabis, there are no new taxes involved.

Initiative 34 (psilocybin): Yes. Medical psilocybin would be subject to a 15% excise tax.

We defer to the experts at the Drug Policy Alliance (DPA), who have the most accurate information available:

Psilocybin is the main ingredient found in several types of psychoactive mushrooms, making it perhaps the best-known naturally-occurring psychedelic drug.

Although psilocybin is considered active at doses around 3-4 mg, a common dose used in clinical research settings ranges from 14-30 mg. Its effects on the brain are attributed to its active metabolite, psilocin.

Psilocybin is most commonly found in wild or homegrown mushrooms and sold either fresh or dried. The most popular species of psilocybin mushrooms is Psilocybe cubensis, which is usually taken orally either by eating dried caps and stems or steeped in hot water and drunk as a tea, with a common dose around 1-2.5 grams.

For more in-depth information, see this Psilocybin Mushrooms Fact Sheet published by DPA.

Leaflys coverage of psilocybin and the medical uses of psychedelics includes these articles:

Silluh-SIGH-bin. Well go with author Michael Pollans pronunciation in this YouTube clip:

IP 34, medical psilocybin legalization:

IP 44, all-drug decrim:

IP 34, medical psilocybin legalization:

IP 44, all-drug decrim:

IP 34, medical psilocybin legalization:

IP 44, all-drug decriminalization:

IP 34, medical psilocybin legalization:

IP 44, all-drug decriminalization:

By submitting this form, you will be subscribed to news and promotional emails from Leafly and you agree to Leafly's Terms of Service and Privacy Policy. You can unsubscribe from Leafly email messages anytime.

Go here to read the rest:

Election 2020: Oregon psilocybin and drug decriminalization initiatives guide - Leafly

Conservation NGOs welcome the reopening of intra-provincial nature-based tourism in no touch economy – Phoenix Sun

Posted on by

The COVID-19 global pandemic has affected almost every aspect of life. In South Africa, alone, the economic effects are devastating with the GDP expected to decline by between eight and 10 percent in 2020. Job losses are estimated at over a million and more than 160, 000 businesses are expected to close their doors.

Under lockdown level three, many sectors have been allowed to trade or operate to some degree, which may have salvaged some businesses and prevented the further loss of jobs.

However, the tourism and leisure sectors have remained closed for months, impacting on thousands of jobs and with concomitant impacts on the fiscus and the wellbeing of millions of South Africans.

Despite concerns over job losses in major South African industries in recent years, the tourism sector has demonstrated resilience and, in 2017, the sector created 31, 752 new jobs which was the most number of net new jobs generated by tourism within a year in at least the previous eight years.

Nature-based tourism refers to all forms of tourism where relatively undisturbed natural environments form the primary attraction or setting.

The wildlife and nature-based tourism sectors specifically support a wide number of associated industries and sectors, such as the conservation sector, through income generation for park management, wildlife protection, anti-poaching and to some degree border control through the management of human movement in transfrontier parks.

For years, national and provincial conservation agencies have been generating significant revenue through nature-based tourism that contributes substantially to conservation management.

Game reserves in South Africa also generate significant benefits to the surrounding communities who contribute to goods and services consumed by visitors. In the absence of economic activity in these parks, there is increased risk of poaching, illegal resource extraction and park invasion.

Years of engaging communities to share in the benefits arising from conservation and nature-based tourism equitably will be undone if protected areas lose their economic value to the communities who depend on them, and should illegal resource use become their only means of survival.

It must be noted that many people employed in the nature-based tourism sector are unskilled/ semi-skilled and are usually breadwinners in their families. Reopening local tourism may not contribute to securing employment for many, and to securing livelihoods in the most vulnerable households and regions.

SANParks, as the custodian of about 70 percent of South Africas state-owned protected area network, derives 80 percent of its income from nature-based tourism activities.

A significant component of this revenue funds park management, anti-poaching, management of marine protected areas, ranger patrol and protection services including the aircraft and associated rhino security technologies as well as management of wildlife.

There are many community-owned reserves that generate income for clinics, schools, community recreation facilities as well many jobs linked to goods and services associated with these reserves, including catering and accommodation.

Several of these community-owned reserves are linked to national and provincial parks and benefit from visitors to parks or their own concessionaire managed lodges.

ALSO READ: A virtual expo of KZN tourism products for global buyers

Nature-based tourism is also a major outlet for people,who have been confined in urban areas. About 70 percent of visitors to national parks are local tourists and thus, the tourism sector can continue to support thousands of livelihoods even before our borders reopen.

The consequences of any extended lockdown for the wildlife and nature-based tourism sector, and by extension to the entire tourism industry, will be dire and potentially devastating as a result of:

Reduced income for conservation NGOs, who play a significant role in biodiversity conservation and community conservation in South Africa and are major employers in the sector.

The conservation NGOs listed below, therefore welcome the announcement by the minister for tourism that intra-provincial leisure travel may soon open up, under strict conditions, to ease the economic impact of COVID-19.

The NGOs fully support the introduction of intra-provincial nature-based tourism into the economic recovery under strong conditions and SOPs.

This is based on their belief that:

The NGOs signed believe that nature-based tourism not only offers guests the opportunities to have enjoyable, safe and healthy leisure time, but is one of the few sectors that stands to revitalise the economy and bring much-needed income back into South African households in the short term.

Allowing an early, phased and safe reopening of the local nature-based tourism sector offers the opportunity to increase the economic, mental and physical well-being of millions of people and sustain the conservation of South Africas natural resources for future generations.

The NGOs welcome the phased reopening of the local nature-based tourism sector and encourage South Africans to support their local nature-based tourism enterprises in the new no touch economy. The signed NGOs are the Endangered Wildlife Trust (EWT), BirdLife South Africa (BLSA), Wildlife and Environment Society South Africa (WESSA) and Wilderness Foundation Africa (WFA).

Go here to read the rest:

Conservation NGOs welcome the reopening of intra-provincial nature-based tourism in no touch economy - Phoenix Sun

PROS Holdings, Inc. Announces Appointment of Catherine A. Lesjak to Board of Directors – Business Wire

Posted on by

HOUSTON--(BUSINESS WIRE)--PROS Holdings, Inc. (NYSE: PRO), a provider of AI-powered solutions that optimize selling in the digital economy, today announced the appointment of Catherine A. Lesjak to its board of directors effective August 3, 2020. Lesjak joins the board as an independent director.

Lesjak is a seasoned finance veteran in the tech industry, having built a 32-year career at HP, Inc. (NYSE: HPQ). Lesjak served in several executive leadership roles during her tenure, including EVP and CFO a role she held for 11 years before serving as interim COO for the company.

She currently serves as a director for technology pioneer and multinational conglomerate GE (NYSE: GE) and SunPower Corporation (NASDAQ: SPWR), a vertically integrated solar company. Lesjak also serves on the board of the Berkeley Haas Business School. She holds a B.S. from Stanford University and an MBA from University of California, Berkeley.

Cathie is an industry veteran who brings substantial financial and operational expertise to the board, said PROS Non-Executive Chairman of the Board Bill Russell. As PROS increases in scale, her experience and knowledge will be a great resource for us as we continue to build even greater long-term value for our shareholders.

I am excited to welcome Cathie to the PROS board, said PROS President and CEO Andres Reiner. Cathie brings a point of view anchored in global scale, execution, repeatability, and commercial success all elements that impact how we drive our SaaS portfolio and scale our global footprint rapidly.

I am truly honored to join the PROS Board of Directors during this inflection point in digital commerce and tremendous need for digital selling solutions, said Lesjak. I look forward to sharing my experience and expertise with PROS to best capitalize on this tremendous market opportunity at hand.

About PROSPROS Holdings, Inc. (NYSE: PRO) provides AI-powered solutions that optimize selling in the digital economy. PROS solutions make it possible for companies to price, configure and sell their products and services in an omnichannel environment with speed, precision and consistency. Our customers, who are leaders in their markets, benefit from decades of data science expertise infused into our industry solutions.

Forward-looking StatementsThis press release contains forward-looking statements, including statements about PROS market opportunity, PROS growth and scalability, the functionality and benefits of AI-powered solutions to organizations generally as well as the functionality and benefits of PROS software products. The forward-looking statements contained in this press release are based upon PROS historical experience and current expectations. Factors that could cause actual results to differ materially from those described herein include, among others, the risks related to the impact of the COVID-19 pandemic, such as the scope and duration of the outbreak and timeframe for economic recovery, the addressability of an organizations AI-powered solution needs, the risks associated with PROS developing and enhancing products with the functionality necessary to deliver the stated results and the risks associated with the complex implementation and maintenance of AI-powered solutions such as PROS software products. Additional information relating to the uncertainty affecting PROS business is contained in PROS filings with the Securities and Exchange Commission. These forward-looking statements represent PROS expectations as of the date of this press release. Subsequent events may cause these expectations to change, and PROS disclaims any obligations to update or alter these forward-looking statements in the future whether as a result of new information, future events or otherwise.

Go here to read the rest:

PROS Holdings, Inc. Announces Appointment of Catherine A. Lesjak to Board of Directors - Business Wire

University Alliance to Deliver Economic and Social Benefits to Wales – Business News Wales

Posted on by

The Governing Body of the University of South Wales (USW) and the Council of the University of Wales Trinity Saint David (UWTSD) have agreed to a strategic alliance which will see both universities working closer together.

The move signals a significant strategic development for the higher education sector landscape in Wales and enables the two largest Post-92 universities to collaborate in order to respond to the economic and societal challenges facing Wales, particularly within a post-Covid context.

In agreeing a Deed of Association, both institutions commit to working together on a national mission to strengthen Wales innovation capacity, supporting economic regeneration and the renewal of its communities.

The Deed of Association acknowledges each institutions autonomy and distinctiveness as strong historic brands which will remain independent, but also marks the collective values of both institutions and their potential to deliver tangible benefits and impact for Wales though collaboration. In particular, working together to drive digital innovation, knowledge transfer, research innovation, workforce development and to provide a ready pipeline of skilled students and graduates, in partnership with employers within priority sectors.

Louise Evans, Chair of the Board of Governors at USW said:

Our aim is to generate innovative solutions to tackle grand challenges. We have a key role to work with the Welsh Government to build capacity and resilience within our communities. Exploiting our joint innovation, applied research and supporting the development of higher-level skills across a range of priority sector areas and linked to employers is key to our collaboration.

The recent Covid-19 engagement has reinforced the need to critically reflect upon the need for all institutions to consider flexible arrangements of association so that universities can make a significant contribution to the national recovery engagement. The need for strong and effective universities that are able to address economic, social and enterprise needs is imperative.

The Venerable Randolph Thomas, UWTSDs Chair of Council added:

This alliance will enable us to make a real difference, particularly in Wales recovery post-Covid, and to assist in developing a sustainable future for the communities we serve, to renew our learning communities and to develop their wellbeing and resilience.

The Deed of Association will build capacity and subject excellence, creating a strong resource base for development and inward investment. It will enable the universities to develop a more diverse entrepreneurial knowledge-based economy; building further on their track record for graduate start-ups.

It will also facilitate the development of a strong base for applied innovation and enterprise as well as a range of educational programmes and lifelong learning opportunities to further social capital and new innovative economic, environmental, cultural and social activity. Working with a range of stakeholders within key sectors across Wales it will address inequalities through widening access and promoting social inclusion and justice.

Professor Julie Lydon, OBE, Vice-Chancellor of USW said:

Both USW and UWTSD are significant players within higher education provision in Wales. Both represent a strong voice for the Post-92 sector and define a very clear agenda for economic and social change in Wales. The opportunity of crafting a new direction of travel which addresses the planning and delivery of education and skills development across further, higher and employment-based education through Wales will have a significant impact and will deliver key outcomes which will support economic and civic regeneration.

Professor Medwin Hughes, DL, Vice-Chancellor of UWTSD added:

Wales needs to be innovative in its educational system and delivery frameworks in order to establish inter and intra-regional groupings which will enhance economic delivery, support social capital and drive forward greater regional Post-16 educational pathways. In doing so, we will secure greater synergy in our skills delivery and establish far stronger strategic partnerships with government and employers.

Read more:

University Alliance to Deliver Economic and Social Benefits to Wales - Business News Wales

Gene therapy reverses memory loss from Alzheimer’s in mice – BioNews

Posted on by

3 August 2020

Memory loss has been reversed in mice with Alzheimer's disease following gene therapy.

A study led bybrothersProfessor Lars Ittner and Dr Arne Ittner of the Macquarie University Dementia Research Centre in Sydney Australia, has shown that the gene therapy not only halts the progression of memory loss, but it can also reverse the effects when applied to mice with advanced Alzheimer's disease.

Discussing the findings, ProfessorIttner said: 'We were completely surprised. They actually recovered their memory function and their ability to learn returned. So, two months after we treated the mice at very old ages, these mice suddenly behaved like their normal siblings.'

By introducing genetic material into the cells of affected mice, the researchers were able to activate an enzymeknown as p38gamma. Previous research by the team revealed that this enzyme, when activated, is protective against the development of Alzheimer's disease. Their latest research builds on this, using gene therapy to enhance the activity of p38gamma in mice with established memory loss.

Results from the study suggest that this gene therapy may be useful in treating other forms of dementia, such as frontotemporal dementia, which typically affects a younger population. As there were no adverse events reported in the mice, even those treated with high doses over a longer period, the team are planning to trial the therapy in humans.

'There is no comparable therapy out there and no other gene therapy either,' said ProfessorIttner. 'This provides hope, as there is a lot of therapy out there focussed on prevention, but not much for those already affected by the disease.'

'It will be exciting to see how over ten years of basic research to understand the mechanisms of Alzheimer's disease will finally transition intoclinical developmentto eventually benefit those most in need, people living with dementia' he added.

The study was published in the journal Acta Neuropathologica.

Visit link:

Gene therapy reverses memory loss from Alzheimer's in mice - BioNews

Hemophilia Gene Therapy Industry Market Analysis by Size, Share, Growth, Application, Segmentation and Forecast to 2025 – Express Journal

Posted on by

Global Hemophilia Gene Therapy Industry market Report 2020 presents critical information and factual data about the Hemophilia Gene Therapy Industry market, providing an overall statistical study of this market on the basis of market drivers, market limitations, and its future prospects. The widespread Hemophilia Gene Therapy Industry market opportunities and trends are also taken into consideration in Hemophilia Gene Therapy Industry industry. with growth trends, various stakeholders like investors, traders, suppliers, SWOT analysis Opportunities and Threat to the organization and others.

The Hemophilia Gene Therapy Industry market report comprises of the key trends which influence the industry growth with respect to the regional terrain and competitive arena. The study highlights the opportunities that will support the industry expansion in existing and untapped markets along with the challenges the business sphere will face. Besides this, the report also offers an intricate analysis of case studies including those of COVID-19 pandemic, with the aim to provide a clear picture of this industry vertical to all shareholders.

Pivotal pointers from COVID-19 impact assessment:

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/160085

Analysis of the regional terrain:

Highlights of the Hemophilia Gene Therapy Industry market report:

Key Coverage of report:

Impact of the latest technological innovations on the Hemophilia Gene Therapy Industry market

Key growth strategies adopted by the prominent market players to address the challenges and restraints put forward by the COVID-19 pandemic

Historical and current trends likely to affect the overall market dynamics of the Hemophilia Gene Therapy Industry market

Growth assessment of the various market segments over the forecast timeline

Regional and global presence of major market players in the Hemophilia Gene Therapy Industry market

Table of Content:

1 Hemophilia Gene Therapy Industry market Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of Hemophilia Gene Therapy Industry market

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the Hemophilia Gene Therapy Industry industry

1.4 Methodology of The Study

1.5 Research Data Source

2 Executive Summary

2.1 Market Overview

2.1.1 Global Hemophilia Gene Therapy Industry market Size, 2015 - 2020

2.1.2 Global Hemophilia Gene Therapy Industry market Size by Type, 2015 - 2020

2.1.3 Global Hemophilia Gene Therapy Industry market Size by Application, 2015 - 2020

2.1.4 Global Hemophilia Gene Therapy Industry market Size by Region, 2015 - 2025

2.2 Business Environment Analysis

2.2.1 Global COVID-19 Status and Economic Overview

2.2.2 Influence of COVID-19 Outbreak on Hemophilia Gene Therapy Industry Industry Development

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/160085

View post:

Hemophilia Gene Therapy Industry Market Analysis by Size, Share, Growth, Application, Segmentation and Forecast to 2025 - Express Journal

Dyne Therapeutics Appoints Susanna High as Chief Operating Officer – Business Wire

Posted on by

WALTHAM, Mass.--(BUSINESS WIRE)--Dyne Therapeutics, a biotechnology company focused on developing life-transforming therapeutics for patients with serious muscle diseases, today announced that it has appointed Susanna High, MBA, as its chief operating officer. Ms. High has more than two decades of experience leading corporate strategy, portfolio management, business planning and operations for biotechnology companies.

Susannas demonstrated success at innovative biotech companies will be an incredible asset to Dyne as we pursue our goal of building the worlds leading muscle disease company, said Joshua Brumm, president and chief executive officer of Dyne. I look forward to partnering with Susanna and drawing on her depth of experience, particularly in rare diseases, as we work to develop and commercialize modern oligonucleotide therapeutics for serious muscle diseases. I am thrilled to welcome Susanna to the Dyne family.

In her most recent position, Ms. High served as chief operating officer of bluebird bio where her numerous responsibilities included the advancement of the companys severe genetic disease portfolio, leading to the European filing and then approval of ZYNTEGLO, a gene therapy for the treatment of transfusion-dependent beta-thalassemia, as well as overseeing the build-out of its European organization. Before joining bluebird, Ms. High worked in roles of increasing responsibility at Alnylam Pharmaceuticals, including as senior vice president, strategy and business integration, where she led corporate and portfolio strategy, program and alliance management, business planning and information technology. Previously, she supported corporate strategy and business operations at Millennium Pharmaceuticals (now Takeda Oncology). Ms. High holds an M.S. in economics and business management from Bocconi University in Italy and an MBA from the MIT Sloan School of Management.

The progress Dyne has made in its lead programs underscores the potential of the FORCE platform and the companys commitment to transforming the treatment opportunities for individuals living with serious muscle diseases, said Ms. High. This is an exciting time for Dyne as their programs advance towards the clinic, and I am honored to join this committed leadership team to develop potentially life-changing therapies.

About Dyne Therapeutics

Dyne Therapeutics is building a leading muscle disease company focused on advancing innovative life-transforming therapeutics for patients with genetically driven diseases. The Company utilizes its proprietary FORCE platform to overcome the current limitations of muscle tissue delivery with modern oligonucleotide therapeutic candidates. Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Dyne was founded by Atlas Venture and is headquartered in Waltham, Mass. For more information, please visit http://www.dyne-tx.com, and follow us on Twitter, LinkedIn and Facebook.

Original post:

Dyne Therapeutics Appoints Susanna High as Chief Operating Officer - Business Wire

Cell and Gene Therapy Industry Market with manufacturers, Application, regions and SWOT Analysis 2025 – CueReport

Posted on by

Global Cell and Gene Therapy Industry market Report 2020 presents critical information and factual data about the Cell and Gene Therapy Industry market, providing an overall statistical study of this market on the basis of market drivers, market limitations, and its future prospects. The widespread Cell and Gene Therapy Industry market opportunities and trends are also taken into consideration in Cell and Gene Therapy Industry industry. with growth trends, various stakeholders like investors, traders, suppliers, SWOT analysis Opportunities and Threat to the organization and others.

The Cell and Gene Therapy Industry market report comprises of the key trends which influence the industry growth with respect to the regional terrain and competitive arena. The study highlights the opportunities that will support the industry expansion in existing and untapped markets along with the challenges the business sphere will face. Besides this, the report also offers an intricate analysis of case studies including those of COVID-19 pandemic, with the aim to provide a clear picture of this industry vertical to all shareholders.

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/27662

Pivotal pointers from COVID-19 impact assessment:

Request Sample Copy of this Report @ https://www.cuereport.com/request-sample/27662

Analysis of the regional terrain:

Highlights of the Cell and Gene Therapy Industry market report:

Key Coverage of report:

Impact of the latest technological innovations on the Cell and Gene Therapy Industry market

Key growth strategies adopted by the prominent market players to address the challenges and restraints put forward by the COVID-19 pandemic

Historical and current trends likely to affect the overall market dynamics of the Cell and Gene Therapy Industry market

Growth assessment of the various market segments over the forecast timeline

Regional and global presence of major market players in the Cell and Gene Therapy Industry market

Table of Content:

1 Cell and Gene Therapy Industry market Introduction and Market Overview

1.1 Objectives of the Study

1.2 Overview of Cell and Gene Therapy Industry market

1.3 Scope of The Study

1.3.1 Key Market Segments

1.3.2 Players Covered

1.3.3 COVID-19's impact on the Cell and Gene Therapy Industry industry

1.4 Methodology of The Study

1.5 Research Data Source

2 Executive Summary

2.1 Market Overview

2.1.1 Global Cell and Gene Therapy Industry market Size, 2015 - 2020

2.1.2 Global Cell and Gene Therapy Industry market Size by Type, 2015 - 2020

2.1.3 Global Cell and Gene Therapy Industry market Size by Application, 2015 - 2020

2.1.4 Global Cell and Gene Therapy Industry market Size by Region, 2015 - 2025

2.2 Business Environment Analysis

2.2.1 Global COVID-19 Status and Economic Overview

2.2.2 Influence of COVID-19 Outbreak on Cell and Gene Therapy Industry Industry Development

Request Customization on This Report @ https://www.cuereport.com/request-for-customization/27662

Excerpt from:

Cell and Gene Therapy Industry Market with manufacturers, Application, regions and SWOT Analysis 2025 - CueReport

Investing in Advanced Manufacturing to Support Public Health – FDA.gov

Posted on by

By: Stephen M. Hahn, M.D., Commissioner of Food and Drugs, and Anand Shah, M.D., Deputy Commissioner for Medical and Scientific Affairs

Americans may be surprised to learn that many 21st century medical products are still being manufactured using technologies commonly employed since the middle of the last century. These manufacturing platforms are not dynamic and can increase the risk of shortages, limit flexibility during an emergency, and contribute to the high cost of medical products. For the past several years, the U.S. Food and Drug Administration has sought to encourage and facilitate the adoption of advanced manufacturing, which refers to new and emerging approaches for the production of medical technologies.

Advanced manufacturing approaches are applicable to different medical product areas. For example, process intensification methods, such as continuous manufacturing, can simplify and centralize the production of many essential medicines. Likewise, techniques such as 3D printing can help produce patient-specific medical devices. Furthermore, digital and smart design and manufacturing processes also promise to increase efficiency and reduce uncertainty.

The potential public health value of advanced manufacturing is even greater in the context of the ongoing COVID-19 pandemic, which has highlighted the strain on supply chains and the need for adaptive manufacturing systems to accelerate the production of medical countermeasures. The FDA has established a strong regulatory foundation to support the uptake of advanced manufacturing, and COVID-19 provides the unique impetus to spur further advancement of medical manufacturing.

FDA regulations cover both sides of the innovation equation: development (whether the product meets the appropriate statutory standard) and manufacturing (whether quality products can be produced for widespread use). Many manufacturers continue to use the same production techniques that were developed more than 50 years ago. Typical manufacturing processes that use long shipping lines or outsourced supply chains render U.S. manufacturing vulnerable to delays, disruptions, and quality control issues. These existing supply chain vulnerabilities have been exacerbated during the COVID-19 pandemic. Additionally, batch manufacturing lacks the flexibility needed to sustainably produce therapies for the personalized medicine era; this is a significant concern given that the FDA anticipates approving approximately 40 gene therapies in the next few years.

Advanced manufacturing often enables innovation, increases in efficiency, and improved supply chain resiliency for medical products that provide wide-ranging public health benefits. Over the past decade, the FDA made strategic, forward-looking investments in personnel, policies, and processes to create a clear regulatory pathway for innovators across the three medical product areas of drugs, biologics, and devices.

First, the agency recognized that innovators seeking to adopt advanced manufacturing technologies may be concerned about the technical and regulatory challenges associated with transitioning away from their existing platforms. To this end, the FDAs Center for Drug Evaluation and Research (CDER) created the Emerging Technology Program, which has a dedicated team available to provide pre-submission support on issues such as the development of process control measures for continuous manufacturing of drugs. To provide focused expertise for advanced manufacturing of biological products, the FDAs Center for Biologics Evaluation and Research (CBER) established the Advanced Technologies Team, which works with prospective developers on issues such as technical considerations for platform technologies in gene therapy.

Second, the FDA recognizes that policy must keep pace with innovation. To expedite the development of newer technologies, the agency developed a series of leapfrog guidance documents, which the FDA uses to share initial thoughts regarding emerging technologies that are likely to be of public health importance. Such leapfrog guidance documents include the FDAs Center for Devices and Radiological Healths (CDRH) 2017 guidance on Technical Considerations for Additive Manufactured Medical Devices, which encompasses many technologies including 3D printing. The agency has provided further regulatory clarity as technologies mature and are commercialized; for example CDER issued guidance in 2019 on Quality Considerations for Continuous Manufacturing. The FDAs engagement in public dialogue supports the proactive identification and resolution of potential barriers for the transition to advanced manufacturing.

Third, as a science-based agency, the FDA supports research and partnerships that expand the knowledge base for advanced manufacturing. For example, the FDA has used authorities in the 21st Century Cures Act to award research grants to support investigators exploring key questions around monitoring and control techniques for advanced manufacturing platforms. To foster collaborations across the public, private, and non-profit sector, the FDAs Office of the Chief Scientist (OCS) launched a new program for advancing regulatory science in public health and formed partnerships with stakeholders such as America Makes, BioFab USA, the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), and a number of industry organizations and clinical societies. OCS has also spearheaded multiple intramural research programs to help develop the regulatory expertise required to evaluate advanced manufacturing technologies. These initiatives will enable the FDA to identify and address cross-cutting scientific, technical, and regulatory challenges and opportunities for advanced manufacturing.

The COVID-19 pandemic has shown how conventional manufacturing practices and predominantly international supply chains may be a liability for Americas emergency response efforts. In addition to the policy and programmatic foundations described above, the FDA has also taken a number of actions to shore up manufacturing capacity specifically for public health preparedness. For example, CDER entered a multi-year partnership with BARDA, the Biomedical Advanced Research and Development Authority, to explore how continuous manufacturing techniques could improve Americas capacity to rapidly manufacture medical countermeasures during emergency situations. During COVID-19 specifically, OCS and CDRH helped develop a Memorandum of Understanding between the FDA, the National Institutes of Health, and the Department of Veterans Affairs to facilitate information sharing on 3D printing to help support manufacturing of essential medical supplies such as personal protective equipment and medical device parts.

Advances in regulatory science are not an end in themselves. True public health preparedness requires incentives and investments in the technologies that the agency has been promoting for years. Increasing emphasis on domestic manufacturing strengthens our response capability, yet it is not enough to bring supply chains back home. We must also ensure that the renewed focus on the importance of domestic manufacturing capacity is paired with a recognition of the capital requirements and scientific expertise needed to adopt more resilient and efficient platforms.

The FDA is committed to doing its part to foster the adoption of advanced manufacturing technologies. To reduce the burden on innovators, the agency is actively working to ensure international concordance on guidelines for continuous manufacturing as part of the International Council for Harmonisations Q13 proposal. To ensure that best practices are informed by the latest research, the agency is committed to monitoring ongoing grant programs, with the intent of fostering initiatives that can demonstrate tangible improvements in safety, quality, and efficiency. To promote communication about the adoption of best practices and innovative ideas between stakeholders, the FDA will continue to proactively provide forums for scientific discussion, participate in national and international workshops, and collaboratively engage stakeholders.

Because pandemics by nature are unpredictable, our approach to manufacturing must be adaptable. Advanced manufacturing provides an approach for protecting our supply chain and improving our response capacity during crisis situations. By establishing the regulatory foundation, the FDA has created a pathway for industry to continue adopting the needed improvements in manufacturing technology for the benefit of public health.

See the rest here:

Investing in Advanced Manufacturing to Support Public Health - FDA.gov

Genetic Studies Could Pave the Way to New Pain Treatments – Pain News Network

Posted on by

By Dr. Lynn Webster, PNN Columnist

Millions of Americans order DNA test kits to determine their ancestries. Knowing where you come from can be entertaining. However, DNA testing can also help identify your risk of developing some diseases, including chronic pain.

Prenatal testing for genetic disorders is common. But genetic testing is also increasingly used to determine the risk of developing certain diseases or potential responses to specific drugs.

Currently, little is known about how to use genes to make an individual more or less sensitive to pain, or to learn the likelihood that someone will respond in a particular way to an analgesic based on their genetics. The good news is that we are on the cusp of gaining more information about the genes that control pain and pain treatments, and that knowledge should allow us to develop targeted pain therapies.

Most physicians still believe that everyone experiences pain in the same way. Research recently published in Current Biology discovered a genethe so-called "Neanderthal gene"that is associated with increased sensitivity to pain. Recognizing that a mutation of a specific gene can influence pain perception may be illuminating for many members of the medical profession.

Pain specialists have known for a long time that given the same stimulus, some people feel more pain than others. The truth is, there are several genes besides the Neanderthal gene that determine how an individual experiences pain. Some genes increase our sensitivity to pain, while other genes decrease it. Some genes influence how pain is processed, while other genes determine an individual's response to an analgesic.

The ability for an analgesic to provide pain relief in an individual is partially determined by the genetics of the receptor to which the pain medication binds. These genes are different from pain-sensitivity genes. For example, oxycodone may be very effective in relieving pain for one individual, but only partially effective for another.

Optimal pain relief requires recognition that each individual responds uniquely to a given analgesic. Doctors are beginning to provide gene therapy for cancer patients. Advancements in research may someday allow us to do the same for patients with pain.

The array of pain responses to the same stimulus is a major reason why one-size-fits-all dosing of pain medications is flawed. A given dose may leave some patients undertreated and others over-treated. Unfortunately, regulators who set arbitrary dose limits fail to understand or consider this biologic variability.

Differing clinical responses to pain stimuli and medications underscore the need to individualize therapy. Knowing more about the biology of pain can help us to understand each individuals response to painful stimuli and the variable response to any therapy.

How we experience pain is a result of both environmental and genetic features. The genetic factors are what we inherit. Environmental factors which we develop rather than inherit include cultural attitudes, emotions, and individual responses to stress. Our personality and lifes experiences are included in the environmental factors that contribute to our experience of pain. Therefore, pain is a result of genetic and environmental interactions. Both can make an individual more or less sensitive to stimuli or analgesia. It is a complex and dynamic process.

The so-called Neanderthal gene is not a new discovery but was newly recognized in Neanderthals. The discovery is interesting, because it implies the gene has an evolutionary purpose. The gene is known as SCN9. There are several pain syndromes associated with the genetic mutations of the SCN9 gene, including some types of back pain and sciatica. Mutations of this gene can result in the total absence of pain or a heightened pain expression. The type of mutation determines the phenotype (or personal characteristics) of our response to a painful stimulus.

It is unclear how Neanderthals benefited biologically from increased pain sensitivity. As we know, acute pain elicits an alarm and is considered protective. It teaches us to avoid dangers that can threaten our life, and prevents us from walking on a broken leg until it heals sufficiently to bear our weight.

Evolution may not have been concerned about the effects of chronic pain. The Neanderthals' limited life expectancy, and the fact that their survival depended on strong physical conditioning, may have made chronic pain a non-issue. Chronic pain may have made survival difficult, or even impossible, for the Neanderthals.

The recent discovery that Neanderthals had the SCN9 gene should not be surprising, given the fact that modern humans shared a common ancestor with Neanderthals. The Neanderthal gene study is of particular interest to me, because I am working with several companies that are exploring potential drugs to affect the function of the SCN9 gene. The companies have different approaches, but they all are trying to find a way to dial down an individual's sensitivity to painful stimuli.

Since the SCN9 gene can be responsible for the total absence of all pain, as well as several extreme forms of pain, it may be reasonable to target the SCN9 gene to modulate pain.

My hope is that manipulation of the SCN9 gene will reduce pain sensitivity, making it easier to control pain by adjusting the dose and type of drug we prescribe.

It is possible one or more drugs that target the SCN9 gene will be available within the next 4-6 years. If that occurs, it could be game changer for people in pain. We can then thank our Neanderthal ancestors for the evolutionary gift.

Lynn R. Webster, MD, is a vice president of scientific affairs for PRA Health Sciences and consults with the pharmaceutical industry. He is author of the award-winning book, The Painful Truth, and co-producer of the documentary, It Hurts Until You Die. You can find Lynn on Twitter: @LynnRWebsterMD

More here:

Genetic Studies Could Pave the Way to New Pain Treatments - Pain News Network

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector Platform for Next Generation…

Posted on by

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector Platform for Next Generation CAR-T Therapeutics

Oxford, UK 3 August 2020: Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica or the Group), a leading gene and cell therapy group, announced today that it has signed a new Development, Manufacture & License Agreement (DMLA) with Beam Therapeutics Inc. (Beam) (Nasdaq: BEAM), a Cambridge, Mass.-based biotechnology company developing precision genetic medicines through the use of base editing. The DMLA grants Beam a non-exclusive license to Oxford Biomedicas LentiVector platform for its application in next generation CAR-T programmes in oncology and puts in place a three year Clinical Supply Agreement.

Under the terms of the DMLA, Oxford Biomedica will receive an undisclosed upfront payment, as well as payments related to development and manufacturing of lentiviral vectors for use in clinical trials, and certain development and regulatory milestones for products sold by Beam that utilise Oxford Biomedicas LentiVector platform and an undisclosed royalty on the net sales of products sold by Beam that utilise the Groups LentiVector platform.

Oxford Biomedica is currently working on one pre-clinical programme with Beam, and the Agreement allows for the Parties to initiate additional projects in the future.

John Dawson, Chief Executive Officer of Oxford Biomedica, said: Beam Therapeutics is one of the leading next-generation CAR-T developers who deploy a wide range of innovative technologies to bring innovative CAR-T products into development. We are proud to be working with a leader in the field of gene editing technologies, including base editing, and this provides us another valuable opportunity for our LentiVector platform to support innovative product development of CAR-T products.

This is our third announced partnership with leaders in the CAR-T field, building on our longstanding partnership with Novartis and our more recently announced partnership with Bristol Myers Squibb earlier this year. We look forward to supporting the next generation CAR-T programmes at Beam.

-Ends-

Oxford Biomedica plc

John Dawson, Chief Executive OfficerStuart Paynter, Chief Financial OfficerCatherine Isted, Head of Corporate Development & IR

T: +44 (0)1865 783 000T: +44 (0)1865 783 000T: +44 (0)1865 954 161 / E: ir@oxb.com

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

T: +44 (0)20 3709 5700

About Oxford BiomedicaOxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZD1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available atwww.oxb.com

Read more:

Oxford Biomedica Signs Development, Manufacture & License Agreement with Beam Therapeutics Inc., for LentiVector Platform for Next Generation...

AZ partners with Daiichi on ADC therapy – BioPharma-Reporter.com

Posted on by

AstraZeneca has returned to commit approximately $6bn (5.1bn) on Daiichi Sankyos antibody drug conjugate (ADC), after completing another separate multi-billion dollar deal last year with the company.

Yesterdays agreement sees AZ pay Daiichi $1bn upfront, due in three intervals, a further $1bn tied to regulatory approvals, and up to $4bn in sales-related milestones. In return, AZ gets access to DS-1062, a trophoblast cell-surface antigen 2-directed ADC.

The drug candidate is being lined up as a treatment for multiple tumor types, with Daiichi already running Phase I trials against non-small cell lung cancer and exploring the possibility to target breast cancers.

Both companies will jointly develop and commercialize the treatment candidate, except in Daiichis home market, Japan, where it will retain exclusive rights. Daiichi will also be responsible for the production and supply of DS-1062.

With this latest deal, AZ has strengthened its existing collaboration with Daiichi, after the two companies announced a potential $7bn deal last year for another ADC, which the partners recently commercialized as Enhertu (trastuzumab deruxtecan).

The treatment was the lead drug in Daiichis ADC pipeline, with it being approved initially in HER2-positive metastatic breast cancer but going through additional Phase III trials to expand its indication.

As a result of both deals, AZs CEO, Pascal Soriot, was able to point to six potential blockbusters that the company has in its portfolio, whilst also noting the potential of its early- and late-stage pipeline.

The company has been working to bolster its pipeline in oncology through a number of smaller partnership and acquisition deals, which saw AZ acquire the rights to Innates potential first-in-class treatment, currently in Phase II trials, and agree a deal to develop oncolytic virus candidate alongside Transgene.

For Daiichi, the deal means that it has the capital for the further development of its ADC programs and to make deals to expand its own pipeline, such as bolstering its expansion into the gene therapy area.

View post:

AZ partners with Daiichi on ADC therapy - BioPharma-Reporter.com

Suspects in Monroe officer’s line-of-duty shooting appear in court – WTOL

Posted on by

Examiners are determining if the 2 men allegedly involved in Cpl. Renae Peterson's shooting are competent to stand trial. She continues to recover.

MONROE, Michigan Forensic examiners are determining if two men facing charges in the shooting of a Monroe police officer are competent to stand trial.

Kordney McDonald and Kobe Falls appeared in court Monday morning.

McDonald is accused of shooting Corporal Renae Peterson in late May after she was trying to apprehend a carjacking suspect. He is charged with assault with intent to murder. His competency review was adjourned so the forensic center can complete its report.

Falls is charged with armed robbery, assaulting and resisting a police officer. He has not been evaluated yet for competency and the matter is rescheduled for late August.

McDonald and Falls' next court appearance is scheduled for late August.

Both men are reported to be homeless, but were living in the Monroe area, according to the Monroe News.

Peterson, a 16-year veteran of the force, was struck twice during the incident. She underwent several surgical procedures while hospitalized.

According to the Monroe Police Department website, Peterson was named officer of the year in 2016.

The Monroe Police Department's account of events says that, at about 7:57 p.m. on May 24, police received a call of a stolen vehicle in the area of East Second Street and Winchester Street. Officers arrived and spoke with the victim, who said an unknown suspect hit her in the head with a handgun, while stealing her vehicle.

While searching the area, Corporal Peterson found the vehicle on North Dixie Highway at Ternes Drive. The officer attempted to make a traffic stop and called out to the vehicle, at which point police said the suspects began shooting. Corporal Peterson was struck multiple times, at which point, the suspects fled on foot eastbound. The two male suspects later were taken into custody.

Corporal Peterson was transported by Monroe Community Ambulance to a Toledo-area hospital.

Continue reading here:

Suspects in Monroe officer's line-of-duty shooting appear in court - WTOL

Adrian Peterson could benefit from the lack of offseason activities – NBC Sports Washington

Posted on by

For many players on Washington Football Team's roster, the lack of a typical offseason almost certainly has done more harm than good. Washington has one of the youngest rosters in the NFL, full of players that could benefit from every rep that was lost with no minicamp, OTAs and preseason games.

However, the lack of team-organized football activities over the past four months due to the coronavirus pandemic was not the worst thing for one Washington player: Running back Adrian Peterson.

In a Zoom call with local reporters on Friday, Washington running backs coach Randy Jordan said he believes the extra time off for the veteran will actually "rejuvenate" Peterson for the upcoming season.

"In terms of a guy that is older, this is something I feel like will rejuvenate him and hell come back just like he normally does in shape and ready to go," Jordan said.

CLICK HERE TO SUBSCRIBE TO THE WASHINGTON FOOTBALL TALK PODCAST

The running backs coach pointed to the two years of Peterson's career prior to joining Washington in 2018 as to why he feels the extended break could serve 'All Day' well.

In 2016, coming off a career-high in carries, Peterson suffered a torn meniscus, causing him to miss all but three games. In 2017, Peterson signed with the Saints, but only saw a handful of touches before getting traded to Arizona in Week 6. Over that two year span, Peterson had a total of just 193 carries, far less than he had during any singular season prior to that point.

"His longevity, people will not talk about this, is he had a stretch where he did not play a lot of football," Jordan said."In terms of that, he was able to pretty much get rejuvenated."

Peterson arrived in Washington the following season as a late camp addition. Frankly, Washington only signed the veteran back because then-rookie Derrius Guice suffered a torn ACL during the preseason.

Over the past two seasons, Peterson has been arguably Washington's most productive weapon on offense. In 2018, he immediately emerged as Washington's lead back and topped 1,000 yards for the eighth time in his career. Last year, he still finished with over 850 yards on the ground despite Washington having the lowest-scoring offense in the NFL.

Peterson's resume speaks for itself. He's a future Hall of Famer and arguably the best running back of the 21st century. He already ranks in the top 5 all-time for rushing yards and rushing touchdowns and will almost certainly moveup on both those lists before he hangs up the cleats.

However, while the running back may not want to admit it, very few running backs in the past have been productive at his current age. Peterson turned 35 in March. Only two running backs, John Henry Johnson and Washington great John Riggins, have topped the thousand-yard mark at age 35 or older.

Washington doesn't need Peterson to be a 1,000-yard rusher in 2020. Guice is fully healthy. Third-round pick Antonio Gibson has earned nothing but praise since arriving in Washington. Bryce Love hasfinally recovered from his knee injury in 2018, and the team signed two veterans, J.D. McKissic and Peyton Barber, in free agency.

But as Peterson has proved over the past two seasons, the inevitable 'Father Time' can wait a little longer. Jordan has little doubt that theageless wonder can still produce for Washington this season.

"When God made him, he just said 'hey, you a football player,'" Jordan said. "And gave him all the tools, the physical statue, the speed, the vision, being able to understand angles, a natural runner.Just God-given ability, things you cannot coach."

Stay connected to the team with the MyTeams app.Click hereto download for comprehensive coverage of your teams.

MORE WASHINGTON FOOTBALL NEWS:

Originally posted here:

Adrian Peterson could benefit from the lack of offseason activities - NBC Sports Washington